Search
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalIn contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamideLevocetirizine
go.drugbank.com/drugs/DB06282ApprovedInvestigational[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Products: LEVOCETIRIZINA EGApixaban
go.drugbank.com/drugs/DB06605ApprovedInvestigationalApixaban was approved by the FDA on December 28, 2012[L6043]. … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic
Products: APIXABAN EGValsartan
go.drugbank.com/drugs/DB00177ApprovedInvestigational[A174124,A173869] Valsartan was initially approved in 1996 in Europe for the treatment of hypertension in adults. Shortly after, in 1997, this drug was approved in the United States. … [A174157,A174160,A174163] Improvements in chronic kidney disease with valsartan include both clinically and statistically significant decreases in urinary albumin and protein excretion in patients diagnosed
Synonyms: N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, (S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valineMixtures: VALSARTAN E IDROCLOROTIAZIDE EG, VALSARTAN E IDROCLOROTIAZIDE EGSimvastatin
go.drugbank.com/drugs/DB00641ApprovedInvestigational[A181087, A181406] Simvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [rosuvastatin], [fluvastatin], and [lovastatin] are considered first-line … clinical studies to result in a 45.8% to 54.6% decrease in LDL cholesterol levels, while simvastatin has been found to have an average decrease in LDL-C of ~35%.
Mixtures: EZETIMIBE E SIMVASTATINA EG, EZETIMIBE E SIMVASTATINA EGProducts: SIMVASTATINA EGCephalexin
go.drugbank.com/drugs/DB00567ApprovedInvestigationalVet approved[A179083,L6547] Cephalexin was approved by the FDA on 4 January 1971.[L6547]
Synonyms: (6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidProducts: LUPICEFF ER, CEFALON ® ERSildenafil
go.drugbank.com/drugs/DB00203ApprovedInvestigationalThe result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension … the public in 1998 [A175732], continues to see millions of prescriptions written for it internationally.
Categories: Drugs Used in Erectile DysfunctionProducts: SILDENAFIL EG, SILDENAFIL EG STADA ITALIATrimetazidine
go.drugbank.com/drugs/DB09069ApprovedInvestigationalTrimetazidine is a piperazine derivative indicated for the symptomatic treatment of stable angina pectoris in patients inadequately controlled or intolerant to first line therapies. … However, it has been approved in France since 1978.[L33020]
Titanium dioxide
go.drugbank.com/drugs/DB09536ApprovedTitanium dioxide, also known as titanium(IV) oxide or titania, is the naturally occurring oxide of titanium. It is used as a pigment under the names titanium white, Pigment White 6 (PW6), or CI 77891. It is typically extracted from ilmen...
Mixtures: Avon Anew Line Eliminator Neo-retinol Line Plumper SPF 15, Line Defiance Makeup SPF 8Categories: Compounds used in a research, industrial, or household setting